新銳醫藥:2023年報
Xinrui Pharmaceuticals (06108) announced annual results. The net loss attributable to shareholders was about HK$22.2 million, a year-on-year narrowing of about 71.5%
According to the Zhitong Finance App, Xinrui Pharmaceutical (06108) announced results for the year ended December 31, 2023, with revenue of about HK$50.2 million, a year-on-year decrease of 44.1%; net loss attributable to the company's owners was about HK$22.2 million, a year-on-year decrease of about 71.5%; and a loss of 1.33 HK cents per share. The decline in revenue was mainly due to the further strengthening of the hierarchical classification management policies for the adoption of antimicrobials in many regions of mainland China, and the adverse effects continued. As a result, demand for the Group's main product, second-generation cephalosporin products (1.0g), declined this year.
NEW RAY MEDIC: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
New Ray Medicine International Forecasts Decline in 2023 Loss
New Ray Medicine International Holding (HKG:6108) expects a net loss of up to HK$30 million for the year 2023, down from HK$77.9 million in 2022, a March 15 filing on the Hong Kong bourse by the pharm
Xinrui Pharmaceuticals (06108.HK) expects a sharp reduction in annual losses
Gelonghui, March 15, 丨 Xinrui Pharmaceuticals (06108.HK) announced that the company expects to record a net loss of no more than HK$30.0 million for the year ended 31 December 2023, while in the previous year, the Group recorded a net loss of approximately HK$77.9 million. The sharp reduction in expected losses for fiscal year 2023 is mainly due to (i) no recording of equity settlement expenses on a share-based basis. The relevant expenses for FY2022 were approximately HK$10.4 million, as confirmed by the Group granting share options to directors and employees in FY2022, and the Group did not record any in FY2023
NEW RAY MEDIC: INSIDE INFORMATION - SUBSTANTIAL REDUCTION IN LOSS
Xinrui Pharmaceuticals (06108.HK) will hold a board meeting on March 25 to approve the annual results
Gelonghui, March 13, 丨 Xinrui Pharmaceutical (06108.HK) issued an announcement. The board of directors will meet on March 25, 2024 to consider and approve the Group's annual results and publication for the year ended December 31, 2023, and to consider whether to pay a final dividend (if any).
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Investors Don't See Light At End Of New Ray Medicine International Holding Limited's (HKG:6108) Tunnel And Push Stock Down 34%
New Ray Medicine International Holding Limited (HKG:6108) shareholders won't be pleased to see that the share price has had a very rough month, dropping 34% and undoing the prior period's positive per
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guotai Junan: The pharmaceutical sector valuation system has entered a small cycle of grasping business operations during a relatively stable period
The Zhitong Finance App learned that Guotai Junan released a research report saying that in 2019-2023, the collection, epidemic, etc. affected industries. It is anticipated that 2024, regardless of whether it has had the greatest positive or negative impact, has passed, returning to the main logic driven by healthcare demand.
CITIC Construction Investment Pharmaceutical's 24-year outlook: moderate growth in the industry, and multiple main lines are expected to take turns
The Zhitong Finance app learned that CITIC Construction Investment released a research report saying that it is optimistic about the pharmaceutical sector in '24 and is optimistic about opportunities for alternating performance in various main lines, such as innovation, overseas travel, improvement, and undervaluation.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Bank of China Fund Zheng Ning: Optimistic about the pharmaceutical industry's reversal, in-hospital product-side companies, especially innovative drugs, are worth paying attention to
Recently, Bank of China Fund Zheng Ning said in an in-depth interview that in the next rise in the pharmaceutical industry, the hospital's product-side companies, especially innovative drugs, are expected to take the lead.
CITIC Construction Investment: Positive year-on-year growth in pharmaceutical revenue in the first three quarters favors prescription drugs, traditional Chinese medicine, etc.
The overall sector's revenue in the first three quarters of 2023 achieved positive year-on-year growth, and the growth rate declined in the third quarter. The growth rate slowed mainly due to increased compliance requirements, but the downturn was not overshadowed, and immediate demand and innovation drove the industry's Q3 revenue to continue to grow.
CITIC Construction Investment: Innovative pharmaceutical companies are still optimistic about segments such as prescription drugs and medical devices on the high-value investment track
The Zhitong Finance App learned that CITIC Construction Investment released a research report stating that last week it focused on reviewing the mid-term business conditions of pharmaceutical companies and innovative pharmaceutical companies.
No Data